logo
Share SHARE
FONT-SIZE Plus   Neg

Galectin Therapeutics Names Jack Callicutt CFO - Quick Facts

Galectin Therapeutics (GALT), the developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced the appointment of Jack Callicutt to the position of Chief Financial Officer, effective July 1, 2013.

Callicutt will lead the Company's financial activities, including financial reporting, accounting, risk management, public company governance, interaction with capital markets, and public and investor relations.

Callicutt has over 22 years of public and private company experience including more than a decade of audit, tax, and SEC registrant experience with a major accounting firm. He was most recently CFO for REACH Health, Inc., a telemedicine firm, where he completed a $4 million private placement.

Previous positions include CFO of Vystar Corporation, a public medical device company whose latex products are devoid of antigenic proteins, where he led all areas of financial reporting, accounting, treasury, risk management and administration and secured over $4.5 million in financing. Previous experiences also include CFO roles at private companies including IVOX and Tikvah Therapeutics, and at Coratus Genetics, a publicly traded biopharmaceutical company.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
British lender Lloyds Banking Group Plc. Friday reported higher profit in its first half, benefited by increased net interest income and margin as well as lower impairment. Looking ahead, the company lifted its net interest margin forecast. Amgen reported an increase in second-quarter profit, driven by sales of arthritis drug Enbrel and osteoporosis treatments Xgeva and Prolia, and improved margins. Both earnings and sales topped Wall Street estimates. Electronic Arts Inc. (EA) on Thursday reported an increase in profit for the first quarter, reflecting continued strong digital revenues, with both earnings and revenues topping Wall Street estimates. However, shares of the company fell over 4 percent, after having detailed a weak outlook. Redwood...
comments powered by Disqus
RELATED NEWS
Trade GALT now with 
Follow RTT